lindane - Profile

What are the generic sources for lindane and what is the scope of patent protection?

Lindane is the generic ingredient in four branded drugs marketed by Reed And Carnrick, Sola Barnes Hind, Olta Pharms, Wockhardt Bio Ag, and Stiefel, and is included in twelve NDAs. Additional information is available in the individual branded drug profile pages.

Summary for lindane

US Patents:	0
Tradenames:	4
Applicants:	5
NDAs:	12

US Patents and Regulatory Information for lindane

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Reed And Carnrick	KWELL	lindane	CREAM;TOPICAL	084218-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Reed And Carnrick	KWELL	lindane	CREAM;TOPICAL	006309-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sola Barnes Hind	GAMENE	lindane	LOTION;TOPICAL	084989-001	Approved Prior to Jan 1, 1982		DISCN	No	No

Lindane: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Executive Summary

Lindane, a historically utilized pesticide and limited pharmaceutical treatment, faces increasing regulatory restrictions owing to environmental and safety concerns. Although initially used for scabies and lice treatment, its global market has diminished significantly. The potential for new formulations or indications is minimal due to safety issues. Conversely, the withdrawal of lindane from many markets presents opportunities for generic manufacturers and alternative treatment providers. This article assesses the current investment landscape, market dynamics, and financial trajectory of lindane from a business perspective, considering regulatory shifts, market demand, and competitive forces.

---

1. Introduction: Scope and Relevance

Lindane (gamma-hexachlorocyclohexane) was once widely used in agriculture and medicine. While pharmaceutical applications persisted in limited regions, environmental and health concerns have led to bans and restrictions, significantly affecting investment prospects. For stakeholders, understanding the evolving regulatory climate and market fundamentals is essential for informed decision-making.

---

2. Regulatory Landscape and Impact on Market Dynamics

2.1 Global regulatory status of lindane

Region	Regulatory status	Key dates	Notes
European Union	Banned since 2008 (Regulation (EC) No 1107/2009)	2008	Ban on all uses, including medicinal
United States	Withdrawn from OTC use in 2003; remaining in some imports for limited veterinary use, now under review	2003	Not approved for pharmaceutical use since 2003
Australia	Banned since 2016	2016	Complete ban on use
India	Restricted, with some pharmaceutical use	2015–2022	Limited, under strict regulation
Developing countries	Varying policies, some restrictions	N/A	Potentially higher use owing to regulatory gaps

Implications:
Most developed markets have stringent bans on lindane, sharply reducing pharmaceutical and agricultural use. The regulatory environment signals declining prospects for investment and new product development. The sustained restrictions contribute to a shrinking market and increased liability risks.

2.2 Regulatory pathway challenges for new formulations

• Approval hurdles: Given the known safety concerns, gaining approval for new lindane formulations or indications remains unlikely.
• Environmental restrictions: Civil and environmental liabilities deter manufacturing operations.
• Legal liabilities: Historical litigation and bans heighten compliance risks for investors.

---

3. Market Dynamics

3.1 Pharmaceutical Market: Current Demand and Supply

Aspect	Details	Impact on Investment
Demand	Limited to residual markets; primarily certain developing countries	Very low in developed markets; niche focus
Supply	Dominated by manufacturers in India, China, and regulatory skeptics	Diminishing over time
Technological alternatives	Permethrin, ivermectin, others	Competitive displacement

Summary:
Pharmaceutical demand predominantly exists in markets with lax regulation or outdated stockpiles. Market share is eroding due to safer alternatives, leading to declining revenues. Entry barriers are high for new competitors because of regulatory and safety concerns.

3.2 Agricultural and Pesticide Market

• Market size: Once significant, now negligible due to bans; replaced by pyrethroids and organophosphates.
• Growth prospects: Negative, owing to bans; no new market entry anticipated.
• Illegal or black market: Prominent in certain regions but risky and unstable.

Impact:
Investment in lindane-based pesticides is non-viable; the focus has shifted entirely to decommissioned stockpile management.

3.3 Market Trends and Future Outlook

Trend	Effect	Source
Regulatory reinforcement	Reduced use and market contraction	[1], [2]
Development of safer alternatives	Declining lindane dependence	[3]
Environmental cleanup initiatives	Decommissioning lindane stockpiles	[4]

Forecast (Next 5-10 Years):

• Continued decline in pharmaceutical and pesticide markets for lindane.
• Focus on environmental remediation, which may offer limited niche investment opportunities around waste disposal rather than product sales.

---

4. Financial Trajectory and Investment Opportunities

Scenario	Investment Outlook	Potential Returns	Risks
Market Exit and Decommissioning	Low or negative residual value; costs outweigh benefits	Negative cash flows; limited upside	Regulatory liabilities, environmental liabilities
Niche Medical Use (Limited) in Developing Countries	Very marginal	Low to negligible	Regulatory, safety, and legal hurdles
Development of Alternatives	High risk, high reward	Dominant players capture the market	R&D costs, regulatory challenges
Environmental & Waste Management	Emerging opportunity	Moderate, related to remediation projects	Contracting governmental or NGO funding, regulatory hurdles

Indicative Investment Figures:

• Decommissioning and disposal costs: Estimated between $5–10 million per site (per environmental agencies, e.g., EPA).
• Limited residual market value: Minimal or none; potential salvage of stored stocks in some regions could yield marginal returns if markets reopen, which is unlikely.

Commercial prospects:
Investments centered on environmental cleanup and remediation are more promising than drug or pesticide sales, given the current regulatory climate.

---

5. Comparison with Similar Classes of Chemicals

Chemical	Regulatory Status	Market Trajectory	Main Competing Substitutes	Investment Landscape
Lindane	Banned or restricted globally	Declining	Permethrin, ivermectin	Very low, mainly environmental
DDT	Banned globally	Abandoned	Modern pest controls	Limited to legacy environmental issues
Organophosphates	Restricted in many regions	Stable decline	Biological alternatives	Niche, with ongoing regulation

Insight:
Lindane's trajectory parallels other persistent organic pollutants (POPs), with declining markets and increasing environmental liabilities.

---

6. Key Market Drivers & Barriers

Drivers

• Global shifts toward safer, environmentally sustainable products
• Environmental remediation efforts for stored stockpiles
• Regulatory bans in major markets reduce supply and demand

Barriers

• Environmental liabilities and legal liabilities
• Limited residual market demand
• Negative perception and health concerns limiting market growth**

---

7. Recommendations for Stakeholders

Stakeholder	Recommendations	Rationale
Investor	Focus on environmental cleanup projects	Low regulatory risk, potential government support
Pharmaceutical Companies	Discontinue lindane manufacturing or sales	High regulatory hurdles, minimal market
Regulatory Bodies	Continue enforcement, decommission stockpiles	Public health priority
Environmental Agencies	Develop funding programs for remediation	Addresses environmental liabilities

---

8. Comparative Analysis: Lindane vs. Alternatives

Parameter	Lindane	Permethrin	Ivermectin	Piperonyl Butoxide (PBO)
Safety Profile	Known safety concerns	Safer	Safer	Safer
Regulatory Status	Restricted/Banned	Approved	Approved	Approved with restrictions
Market Volume	Declining	Growing in some segments	Growing	Stable or declining
Cost	Low (existing stock)	Moderate	High	Moderate

---

9. FAQs

Q1: Is there any potential for lindane to return to the pharmaceutical market?
A: Highly unlikely due to persistent safety concerns and regulatory restrictions; residual demand may exist but is insignificant.

Q2: Are there any ongoing legal liabilities associated with lindane stocks?
A: Yes, especially in regions with environmental bans; liability risks include cleanup costs and potential litigation.

Q3: Can the environmental remediation of lindane stockpiles offer a profitable investment?
A: Potentially, as contracts exist with government agencies for cleanup efforts, but margins are often limited, and funding depends on public policy.

Q4: Which regions present the best opportunities for investment related to lindane?
A: Emerging markets focusing on stockpile cleanup or transitioning from legacy uses, primarily in parts of Asia and Africa.

Q5: How does the decline of lindane influence the development of safer alternatives?
A: It accelerates R&D investment in newer, environmentally friendly compounds that are better tolerated by regulators and markets.

---

10. Key Takeaways

• Regulatory restrictions dominate the lindane market landscape, leading to a rapid decline in use and sales.
• The primary investment opportunities are in environmental remediation and stockpile management rather than product sales.
• Developers face significant regulatory and safety hurdles for new formulations, with minimal prospects for renewed pharmaceutical or agricultural markets.
• Stakeholders should prioritize environmental cleanup projects and monitor policy developments for future opportunities.
• Alternative pest control and pharmaceutical agents serve as viable substitutes, further diminishing lindane's market relevance.

---

References

[1] European Chemicals Agency. (2008). Regulation (EC) No 1107/2009.
[2] U.S. Environmental Protection Agency. (2003). Lindane Registration Review.
[3] World Health Organization. (2018). Alternatives to Lindane for pesticide use.
[4] International Agency for Research on Cancer. (2014). Lindane: Carcinogenicity Review.